These results confirm the mutual interaction among mTOR, mitochondria, and the de novo purine biosynthetic pathway, and further studies are needed to explore the therapeutic effects of inhibitors for purine biosynthesis and the underlying mechanism of mTOR-mediated purinosome-mitochondria localization and purine metabolism in cancers. This evidence concerns the gene MTOR and cancer.